Pharmacokinetics and dosage adjustment in patients with renal dysfunction

European Journal of Clinical Pharmacology

Volumn 65, Issue 8, 2009, Pages 757-773

  Verbeeck, Roger K ^a   Musuamba, Flora T ^b  

^a RHODES UNIVERSITY   (South Africa)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Dosage adjustment; Non renal drug clearance; Pharmacokinetic pharmacodynamic processes; Renal drug clearance; Renal dysfunction

Indexed keywords

ATORVASTATIN; BETA LACTAM ANTIBIOTIC; BLOOD CLOTTING FACTOR 10A; CREATININE; CYSTATIN C; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOKINE; DIGOXIN; DRUG; ENOXAPARIN; ERYTHROMYCIN; ETHAMBUTOL; KETOPROFEN; MEMANTINE; MORPHINE; MORPHINE 6 GLUCURONIDE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER; PARATHYROID HORMONE; PEPTIDE TRANSPORTER 1; PEPTIDE TRANSPORTER 2; PHENAZONE; PHENYTOIN; PINDOLOL; UNINDEXED DRUG; UREA; VALPROIC ACID; WARFARIN;

4 AMINOHIPPURIC ACID CLEARANCE; ACUTE CORONARY SYNDROME; BLOOD BRAIN BARRIER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIET; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY MICROSOME; LIVER MICROSOME; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

BIOLOGICAL MARKERS; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLOMERULAR FILTRATION RATE; HEPATORENAL SYNDROME; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MATHEMATICAL COMPUTING; METABOLIC CLEARANCE RATE; PHARMACOKINETICS; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 70349603042     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0678-8     Document Type: Review

References (139)

1. Thummel KE, Shen DD, Isoherranen N, Smith HE (2006) Design and optimization of dosage regimens: pharmacokinetic data. In: Brunton LL, Lazo LL, Parker KL (eds) Goodman & Gilman's The pharmacological basis of therapeutics, 11 edn. McGraw-Hill, New York, pp 1787-1888
2. J Coresh E Selvin LA Stevens, et al. 2007 Prevalence of chronic kidney disease in the United States JAMA 298 2038 2047 17986697 1:CAS:528: DC%2BD2sXht1yjsLnM 10.1001/jama.298.17.2038 (Pubitemid 350074801)
3. JW Graves 2008 Diagnosis and management of chronic kidney disease Mayo Clin Proc 83 1064 1069 18775206 10.4065/83.9.1064
4. LA Stevens J Coresh T Greene AS Levey 2006 Assessing kidney function-measured and estimated glomerular filtration rate N Engl J Med 354 2473 2483 16760447 1:CAS:528:DC%2BD28XlsVaiurk%3D 10.1056/NEJMra054415 (Pubitemid 43855050)
5. SE Tett CMJ Kirkpatrick AS Gross AJ McLachlan 2003 Principles and clinical application of assessing alterations in renal elimination pathways Clin Pharmacokinet 42 1193 1211 14606929 10.2165/00003088-200342140-00002 (Pubitemid 37491486)
6. PE de Jong RT Gansevoort 2008 Fact or fiction of the epidemic of chronic kidney disease-let us not squabble about estimated GFR only, but also focus on albuminuria Nephrol Dial Transplant 23 1092 1095 18359868 10.1093/ndt/gfn028 1:CAS:528:DC%2BD1cXjs12ltrs%3D (Pubitemid 351767532)
7. F Gaspari N Perico G Remuzzi 1998 Application of newer clearance techniques for the determination of glomerular filtration rate Curr Opin Nephrol Hypertens 7 675 680 9864664 1:STN:280:DyaK1M%2Fot1WrsQ%3D%3D
8. DW Cockroft MH Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41 10.1159/000180580
9. AS Levey JP Bosch JB Lewis T Greene N Rogers D Roth 1999 A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Ann Intern Med 130 461 470 10075613 1:CAS:528: DyaK1MXitFChs7k%3D
10. AS Levey T Greene JW Kusk GJ Beck MDRD Study Group 2000 A simplified equation to predict glomerular filtration rate from serum creatinine J Am Soc Nephrol 11 A0828 [Abstract]
11. AG Bostom F Kronenberg R Eberhard 2002 Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels J Am Soc Nephrol 13 2140 2144 12138147 1:CAS:528: DC%2BD38Xmt1Ogtr8%3D 10.1097/01.ASN.0000022011.35035.F3 (Pubitemid 34790792)
12. S Robert BJ Zarowitz EL Peterson F Dumler 1993 Predictability of creatinine clearance estimates in critically ill patients Crit Care Med 21 1487 1495 8403957 1:STN:280:DyaK2c%2Fgslykug%3D%3D
13. CM Kirkpatrick SB Duffull EJ Begg 1999 Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily Br J Clin Pharmacol 47 637 643 10383541 1:CAS:528:DyaK1MXktFSmtb4%3D 10.1046/j.1365-2125.1999.00938.x (Pubitemid 29257661)
14. JK Aronson 2007 Drug therapy in kidney diesease Br J Clin Pharmacol 63 509 511 17488361 10.1111/j.1365-2125.2007.02917.x (Pubitemid 46632580)
15. S Herget-Rosenthal A Bökenkamp W Hofmann 2007 How to estimate GFR-serum creatinine, serum cystatin C or equations? Clin Biochem 40 153 161 17234172 1:CAS:528:DC%2BD2sXntlOiug%3D%3D 10.1016/j.clinbiochem.2006.10.014 (Pubitemid 46108706)
16. G Filler A Bökenkamp W Hofmann T Lebricon C Martinez-Bru A Grubb 2005 Cystatin C as a marker of GFR-history, indications, and future research Clin Biochem 38 1 8 15607309 1:CAS:528:DC%2BD2cXhtVyqsLbN 10.1016/j.clinbiochem. 2004.09.025 (Pubitemid 39647648)
17. DF Work GJ Schwartz 2008 Estimating and measuring glomerular filtration rate in children Curr Opin Nephrol Hypertens 17 320 325 18408486 10.1097/MNH.0b013e3282fb77f2
18. NL Proulx A Akbari AX Garg A Rostom J Jaffey HD Clark 2005 Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis Nephrol Dial Transplant 20 1617 1622 15855207 1:CAS:528:DC%2BD2MXmsV2htrc%3D 10.1093/ndt/gfh839 (Pubitemid 41418585)
19. DG Waller 2007 Drugs and the kidney: more than a question of dose Br J Clin Pharmacol 64 719 721 18078474 10.1111/j.1365-2125.2007.02987.x (Pubitemid 46934428)
20. DA Sica 2007 Considerations in drug handling in renal disease Clin Pharmacokinet 46 677 679 17655374 1:CAS:528:DC%2BD2sXhtVKgs7%2FK 10.2165/00003088-200746080-00004 (Pubitemid 47204853)
21. A Fuhr A Jetter J Kirchheiner 2007 Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the.,cocktail" approach Clin Pharmacol Ther 81 270 283 17259951 1:CAS:528:DC%2BD2sXisFyrtbc%3D 10.1038/sj.clpt.6100050 (Pubitemid 46174825)
22. AS Gross AJ MacLachlan I Minns, et al. 2001 Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol Br J Clin Pharmacol 51 547 555 11422014 1:CAS:528: DC%2BD3MXltFeit7o%3D 10.1046/j.1365-2125.2001.01390.x (Pubitemid 32862744)
23. Tozer TN, Rowland M (2006) Introduction to pharmacokinetics and pharmacodynamics: the quantitative basis of drug therapy. Lippincott Williams & Williams, Philadelphia, pp 97-100
24. W Lee B Kim 2004 Transporters and renal elimination Annu Rev Pharmacol Toxicol 44 137 166 14744242 1:CAS:528:DC%2BD2cXhvVCkt7k%3D 10.1146/annurev. pharmtox.44.101802.121856 (Pubitemid 38263837)
25. AAK El-Sheikh R Masereeuw FGM Russel 2008 Mechanisms of renal anionic transport Eur J Pharmacol 585 245 255 18417112 1:CAS:528:DC%2BD1cXls1Sntrs%3D 10.1016/j.ejphar.2008.02.085
26. H Koepell K Lips C Volk 2007 Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications Pharm Res 24 1227 1251 10.1007/s11095-007-9254-z 1:CAS:528:DC%2BD2sXnt1Clu7Y%3D (Pubitemid 46876495)
27. GR Wilkinson 1987 Clearance approaches in pharmacology Pharmacol Rev 39 1 47 3554275 1:CAS:528:DyaL2sXktFOjsbo%3D
28. A Baumann 2006 Early development of therapeutic biologics- pharmacokinetics Curr Drug Metab 7 15 21 16454690 1:CAS:528: DC%2BD28Xms1OksQ%3D%3D 10.2174/138920006774832604
29. I Mahmood MD Green 2005 Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins Clin Pharmacokinet 44 331 347 15828849 1:CAS:528:DC%2BD2MXltlCqt7Y%3D 10.2165/00003088-200544040-00001 (Pubitemid 40663681)
30. H Daniel I Rubio-Aliaga 2003 An update on renal peptide transporters Am J Renal Physiol 284 F885 F892 1:CAS:528:DC%2BD3sXjvFGqsrc%3D
31. Braeckman R (2000) Pharmacokinetics and pharmacodynamics of protein therapeutics. In: Reid ER (ed) Peptides and protein drug analysis. Marcel Dekker, New York, pp 633-649
32. Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications, 3rd edn. Lippincott Williams & Wilkins, Philadelphia
33. YWF Lam S Banerji C Hatfield RL Talbert 1997 Principles of drug administration in renal insufficiency Clin Pharmacokinet 32 30 57 9012555 1:CAS:528:DyaK2sXhtVWjsr0%3D 10.2165/00003088-199732010-00002
34. Matzke GR, Comstock TJ (2006) Influence of renal function and dialysis on drug disposition. In: Burton ME, Shaw LM, Schentag JJ, Evans WE (eds) Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 187-212
35. TP Gibson KM Giacomini WA Briggs, et al. 1980 Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient Clin Pharmacol Ther 27 665 670 7371364 1:CAS:528:DyaL3cXks1SqsL8%3D
36. Levy G, Giacomini KM (1981) First-pass effects in health and disease: pharmacokinetics studies on dextropropoxyphene. In: Prescott LF, Nimmo WS (eds) Drug absorption: Proc Edinburgh Int Conf. MTP Press, Lancaster pp 115-122
37. G Bianchetti G Graziani D Brancacci, et al. 1976 Pharmacokinetics and effects of propranolol in terminal uremic patients and in patients undergoing regular dialysis treatment Clin Pharmacokinet 1 373 384 1017154 1:CAS:528:DyaE2sXmsFaruw%3D%3D 10.2165/00003088-197601050-00004
38. G Davies C Kingswood M Street 1996 Pharmacokinetics of opioids in renal dysfunction Clin Pharmacokinet 31 410 422 8968655 1:CAS:528:DyaK2sXjt12rsQ%3D%3D 10.2165/00003088-199631060-00002
39. GJ Muirhead K Wilner W Colburn G Haug-Pihale B Rouvieux 2002 The effect of age and renal and hepatic impairment on the Pharmacokinetics of sildenafil citrate Br J Clin Pharmacol 53 21S 30S 11879256 1:CAS:528:DC%2BD38XislCkt7s%3D 10.1046/j.0306-5251.2001.00029.x (Pubitemid 41712962)
40. MB Kays BR Overholser BA Mueller, et al. 2003 Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin Am J Kidney Dis 42 1253 1259 14655198 1:CAS:528:DC%2BD2cXpsFGr 10.1053/j.ajkd.2003.08.027 (Pubitemid 37486770)
41. PP How JH Fischer JA Arruda, et al. 2007 Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin Clin J Am Soc Nephrol 2 1235 1240 17913970 1:CAS:528:DC%2BD2sXhtlGgsbbL 10.2215/CJN.01580407
42. MacKichan JJ (2006) Influence of protein binding and use of unbound (free) drug concentrations. In: Burton ME, Shaw LM, Schentag JJ, Evans WE (eds) Applied pharmacokinetics and pharmacodynamics-principles of therapeutic drug monitoring. Lippincott Williams, Wilkins, Philadelphia, pp 82-120
43. NS Bricker PAF Morrin SW Kime Jr 1997 The pathologic physiology of chronic Bright's Disease: an exposition of the "intact nephron hypothesis" J Am Soc Nephrol 8 1470 1476 9294841 1:STN:280: DyaK2svktVKhsQ%3D%3D
44. A Periclou D Ventura R Niranjan W Abramowitz 2006 Pharmacokinetic study of memantine in healthy and renally impaired subjects Clin Pharmacol Ther 79 134 143 16413248 1:CAS:528:DC%2BD28XksVGlug%3D%3D 10.1016/j.clpt.2005.10.005 (Pubitemid 43069584)
45. LP Balant P Dayer J Fabre 1983 Consequences of renal insufficiency on the hepatic clearance of some drugs Int J Clin Pharmacol Res 3 459 474 6147317 1:STN:280:DyaL2c3ovVSnsg%3D%3D
46. TP Gibson 1986 Renal disease and drug metabolism Am J Kidney Dis 8 7 17 3524205 1:CAS:528:DyaL2sXkvV2isLY%3D
47. AC Elston MK Bayliss GR Park 1993 Effect of renal failure on drug metabolism Br J Anaesth 71 282 290 8123408 1:STN:280:DyaK2c7mvVyrsg%3D%3D 10.1093/bja/71.2.282
48. TC Dowling AE Briglia JC Fink DS Hanes PD Light L Stackiewicz CS Karyekar ND Eddington MR Weir WL Henrich 2003 Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease Clin Pharmacol Ther 73 427 434 12732843 1:CAS:528:DC%2BD3sXjsVGmtLw%3D 10.1016/S0009-9236(03)00056-0 (Pubitemid 36549827)
49. LA Frassetto S Poon C Tsourounis C Valera LZ Benet 2007 Effects of uptake and efflux transporter inhibition on erythromycin breath test results Clin Pharmacol Ther 81 828 832 17361125 1:CAS:528:DC%2BD2sXmsF2iurc%3D 10.1038/sj.clpt.6100148 (Pubitemid 46788293)
50. AW Dreisbach S Japa AB Gebrekal SE Mowry JJL Lertora BL Kamath AE Rettie 2003 Cytochrome P4502C9 activity in end-stage renal disease Clin Pharmacol Ther 73 475 477 12732848 1:CAS:528:DC%2BD3sXjsVGmtLg%3D 10.1016/S0009-9236(03)00015-8 Letter to the Editor
51. S Stehle J Kirchheiner A Lazar U Fuhr 2008 Pharmacogenetics of oral anticoagulants-a basis for dose individualization Clin Pharmacokinet 47 565 594 18698879 1:CAS:528:DC%2BD1cXhtFylsbjP 10.2165/00003088-200847090-00002
52. RF Frye, et al. 2006 Liver disease Selectivey modulates cytochrome P450- mediated metabolism drugs in liver Clin Pharmacol Ther 80 235 245 16952490 1:CAS:528:DC%2BD28XptFCgu7s%3D 10.1016/j.clpt.2006.05.006 (Pubitemid 44313901)
53. Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147-1161
54. MWE Teunissen D Kampf I Roots, et al. 1985 Antipyrine metabolite formation and excretion in patients with chronic renal insufficiency Eur J Clin Pharmacol 28 589 595 4043202 1:STN:280:DyaL28%2FgsV2msQ%3D%3D 10.1007/BF00544072 (Pubitemid 15030787)
55. FA Leblond L Giroux JP Villeneuve V Pichette 2000 Decreased in vivo metabolism of drugs in chronic renal failure Drug Metab Disp 28 1317 1320 1:CAS:528:DC%2BD3cXnsFOlsLY%3D
56. F Leblond C Guévin C Demers I Pellerin M Gascon-Barré V Pichette 2001 Downregulation of hepatic cytochrome P450 in chronic renal failure J Am Soc Nephrol 12 326 332 11158222 1:CAS:528:DC%2BD3MXhtl2msLs%3D
57. FA Leblond M Petrucci P Dubé G Bernier A Bonnardeaux V Pichette 2002 Downregulation of intestinal cytochrome P450 in chronic renal failure J Am Soc Nephrol 13 1579 1585 12039987 1:CAS:528:DC%2BD38XkvFelsLY%3D 10.1097/01.ASN.0000017575.50319.77 (Pubitemid 34579247)
58. C Guévin J Michaud J Naud FA Leblond V Pichette 2002 Down-regulation of hepatic cytochrome P450 in chronic renal failure: the role of uremic mediators Br J Pharmacol 137 1039 1046 12429576 10.1038/sj.bjp.0704951 1:CAS:528:DC%2BD38XpsVantb8%3D (Pubitemid 35440744)
59. V Pichette FA Leblond 2003 Drug metabolism in chronic renal failure Curr Drug Metab 4 91 103 12678690 1:CAS:528:DC%2BD3sXjtVWmu74%3D 10.2174/ 1389200033489532 (Pubitemid 36443190)
60. H Sun Y Huang L Frassetto LZ Benet 2004 Effects of uremic toxins on hepatic uptake and metabolism of erythromycin Drug Metab Disp 32 1239 1246 1:CAS:528:DC%2BD2cXovFCktb8%3D 10.1124/dmd.104.000521 (Pubitemid 39410907)
61. J Michaud P Dubé J Naud FA Leblond K Desbiens A Bonnardeaux V Pichette 2005 Effects of serum from patients with chronic renal failure on rat heaptic cytochrome P450 Br J Pharmacol 144 1067 1077 15700027 1:CAS:528:DC%2BD2MXjtlaksrw%3D 10.1038/sj.bjp.0706138 (Pubitemid 40593005)
62. H Sun L Frassetto LZ Benet 2006 Effects of renal failure on drug transport and metabolism Pharmacol Ther 109 1 11 16085315 1:CAS:528: DC%2BD2MXht12ktbbM 10.1016/j.pharmthera.2005.05.010 (Pubitemid 41740811)
63. J Michaud J Naud J Chouinard F Désy FA Leblond K Desbiens A Bonnardeaux V Pichette 2006 Role of parathyroid hormone in the down-regulation of liver cytochrome P450 in chronic renal failure J A Soc Nephrol 17 3041 3048 1:CAS:528:DC%2BD28Xht1yjtbrM 10.1681/ASN.2006010035 (Pubitemid 44707764)
64. TD Nolin J Naud FA Leblond V Pichette 2008 Emerging evidence of the impact of kidney disease on drug metabolism and transport Clin Pharmacol Ther 83 898 903 18388866 1:CAS:528:DC%2BD1cXlvFOrtbg%3D 10.1038/clpt.2008.59 (Pubitemid 351704931)
65. E Simard J Naud J Michaud FA Leblond A Bonnardeaux C Guillemette E Sim V Pichette 2008 Downregulation of hepatic acetylation of drugs in chronic renal failure J Am Soc Nephrol 19 1352 1359 18417721 1:CAS:528:DC%2BD1cXovFeks7s%3D 10.1681/ASN.2007090974
66. C Yu JK Ritter RJ Krieg B Rege TH Karnes MA Sarkar 2006 Effect of chronic renal insufficiency on hepatic and renal UDP- glucuronyltransferases in rats Drug Metab Disp 34 621 627 1:CAS:528:DC%2BD28XjtlKnsLk%3D 10.1124/dmd.105.006601
67. TD Nolin K Appiah SA Kendrick P Le E McMonagle J Himmelfarb 2006 Hemodialysis acutely improves hepatic CYP3A4 metabolic activity J Am Soc Nephrol 17 2363 2367 16899515 1:CAS:528:DC%2BD28XpvFOgur8%3D 10.1681/ASN.2006060610 (Pubitemid 44300952)
68. JO Miners PI Mackenzie 1991 Drug glucuronidation in humans Pharmacol Ther 51 347 369 1792239 1:CAS:528:DyaK38Xht1ShsL8%3D 10.1016/0163-7258(91)90065-T
69. MJ Bailey RG Dickinson 2003 Acyl glucuronide reactivity in perspective: biological consequences Chem Biol Interact 145 117 137 12686489 1:CAS:528:DC%2BD3sXis12jt7k%3D 10.1016/S0009-2797(03)00020-6 (Pubitemid 36398426)
70. RK Verbeeck 1982 Glucuronidation and disposition of drug glucuronides in patients with renal failure Drug Metab Disp 10 87 89 1:STN:280: DyaL383jsFChug%3D%3D
71. G Stafanger HW Larson H Hansen K Sorensen 1981 Pharmacokinetics of ketoprofen in patients with chronic renal failure Scand J Rheumatol 10 189 192 7291952 1:STN:280:DyaL38%2FjvFCruw%3D%3D 10.3109/03009748109095297
72. KJ Skeith M Dasgupta R Lange F Jamali 1996 The influence of renal function on the pharmacokinetics of unchanged and acyl- glucuronide ketoprofen enantiomers after 50 and 100 mg racemic ketoprofen Br J Clin Pharmacol 42 163 169 8864313 1:CAS:528:DyaK28XltlGrtrc%3D 10.1046/j.1365-2125.1996.03864.x
73. NG Grubb DW Rudy DC Brater SD Hall 1999 Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination Br J Clin Pharmacol 48 494 500 10583018 1:CAS:528:DyaK1MXmvFalu7o%3D 10.1046/j.1365-2125.1999.00046.x (Pubitemid 29454228)
74. QY Yue I Odar-Cederlöf JO Svensson J Säwe 1988 Glucuronidation of morphine in human kidney microsomes Pharmacol Toxicol 63 337 341 3148914 1:CAS:528:DyaL1MXltVKquw%3D%3D 10.1111/j.1600-0773.1988.tb00965.x
75. AA Raoof LJ Van Obbergh J de Ville de Goyet RK Verbeeck 1996 Extrahepatic metabolism of propofol in man: possible contribution of gut wall and kidney Eur J Clin Pharmacol 50 91 96 8739817 1:CAS:528:DyaK28XjsFWksr0%3D 10.1007/s002280050074 (Pubitemid 26140094)
76. KA McGurk CH Brierley B Burchell 1998 Drug glucuronidation by human reanl UDP-glucuronosyltransferases Biochem Pharmacol 55 1005 1012 9605424 1:CAS:528:DyaK1cXit12qsrs%3D 10.1016/S0006-2952(97)00534-0 (Pubitemid 28167722)
77. JX Mazoit P Sandouk JM Scherrmann A Roche 1990 Extrahepatic metabolism of morphine occurs in humans Clin Pharmacol Ther 48 613 618 2249372 1:CAS:528:DyaK3MXhsFKmsbg%3D
78. TB Vree YA Hekster PG Anderson 1992 Contribution of the human kidney to the metabolic clearance of drugs Ann Pharmacother 26 1421 1428 1477449 1:CAS:528:DyaK3sXltFyisw%3D%3D
79. H Hiraoka K Yamamoto S Miyoshi T Morita K Nakamura Y Kadoi F Kunimoto R Horiuchi 2005 Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain Br J Clin Pharmacol 60 176 182 16042671 1:CAS:528:DC%2BD2MXps1Kkur8%3D 10.1111/j.1365-2125.2005.02393.x (Pubitemid 41075903)
80. GA Verpooten L Verbist AP Buntinx LA Entwistle KH Jones ME De Broe 1984 The pharmacokinetics of imipenem (thienamycin- formamidine) and the renal dehydropeptidase inhibitor cilastin sodium in normal subjects and patients with renal failure Br J Clin Pharmacol 18 183 193 6593092 1:CAS:528: DyaL2cXls1eitb8%3D
81. RH Ho RB Kim 2005 Transporters and drug therapy: implications for drug disposition and disease Clin Pharmacol Ther 78 260 277 16153397 1:CAS:528:DC%2BD2MXpvV2rt78%3D 10.1016/j.clpt.2005.05.011 (Pubitemid 41254111)
82. LZ Benet CL Cummins CY Wu 2003 Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data Curr Drug Metab 4 393 398 14529371 1:CAS:528:DC%2BD3sXotlGrtLg%3D 10.2174/1389200033489389 (Pubitemid 37279364)
83. CY Wu LZ Benet 2005 Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm Res 22 11 23 15771225 1:CAS:528:DC%2BD2MXhtlCks70%3D 10.1007/s11095-004-9004-4 (Pubitemid 40558141)
84. JL Lam H Okochi Y Huanh LZ Benet 2006 In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism characterizing the importance of transporter-enzyme interplay Drug Metab Disp 34 1336 1344 1:CAS:528:DC%2BD28Xnslakurk%3D 10.1124/dmd.106.009258 (Pubitemid 44079874)
85. YY Lau Y Huang L Frassetto LZ Benet 2007 Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers Clin Pharmacol Ther 81 194 204 17192770 1:CAS:528:DC%2BD2sXisFyrtLY%3D 10.1038/sj.clpt.6100038 (Pubitemid 46174816)
86. J Naud J Michaud C Boisvert K Desbiens FA Leblod A Mitchell C Jones A Bonnardeaux V Pichette 2007 Down-regulation of intestinal drug transporters in chronic renal failure in rats J Pharmacol Exp Ther 320 978 985 17135344 1:CAS:528:DC%2BD2sXis1Wgt7g%3D 10.1124/jpet.106.112631 (Pubitemid 46294060)
87. J Naud J Michaud FA Leblond S Lefrancois A Bonnardeaux V Pichette 2008 Effects of chronic renal failure on liver drug transporters Drug Metab Disp 36 124 128 1:CAS:528:DC%2BD1cXmtFGktA%3D%3D 10.1124/dmd.107.018192
88. T Niwa T Miyazaki T Katsuzaki N Tatemichi Y Takei 1996 Serum levels of 3-deoxyglucosoneand tissue contents of advanced glycation end-products are increased in streptozotocin-induced diabetic rats with nephropathy Nephron 74 580 585 8938685 1:STN:280:DyaK2s%2FptlWhsQ%3D%3D 10.1159/000189456
89. R Dzurik V Spustova Z Krivosikova K Gazdikova 2001 Hippurate participates in the correction of metabolic acidosis Kidney Int Suppl 78 S278 S281 11169026 1:CAS:528:DC%2BD3MXhtlKju7g%3D 10.1046/j.1523-1755.2001.07831.x
90. M Gusella M Rebeschini G Cartel E Ferrazzi M Ferrari R Padrini 2005 Effect of hemodialysis on the metabolic clearance of 5-fluorouracil in a patient with end-stage renal failure Ther Drug Monit 27 816 818 16306860 10.1097/01.ftd.0000183384.89275.f4 (Pubitemid 44391741)
91. Michaud J, Nolin TD, Naud J, Dani M, Lafrance JP, Leblond FA, Himmelfarb J and Pichette V (2008) Effect of hemodialysis on hepatic Cytochrome P450 functional expression. J Pharmacol Sci 108(2):157-163
92. RK Verbeeck RA Branch GR Wilkinson 1981 Drug metabolites in renal failure: pharmacokinetics and clinical implications Clin Pharmacokinet 6 329 345 7037261 1:STN:280:DyaL387jslKisA%3D%3D 10.2165/00003088-198106050-00001
93. H McQuay A Moore 1984 Be aware of renal function when prescribing morphine Lancet ii 284 285 10.1016/S0140-6736(84)90323-4
94. R Osborne SP Joel ML Slevin 1986 Morphine intoxication in renal insufficiency: the role of morphine-6-glucuronide Br Med J 292 1548 1549 1:STN:280:DyaL283ksVSrsg%3D%3D 10.1136/bmj.292.6535.1548 (Pubitemid 16080832)
95. J Säwe I Odar-Cederlöf 1987 Kinetics of morphine in patients with renal failure Eur J Clin Pharmacol 32 377 382 3609116 10.1007/BF00543973 (Pubitemid 17077185)
96. R Osborne S Joel K Grebenik D Trew M Slevin 1993 The pharmacokinetics of morphine and morphine glucuronides in kidney failure Clin Pharmacol Ther 54 158 167 8354025 1:STN:280:DyaK3szlvVGktg%3D%3D
97. GW Pasternak RJ Bodnar JA Clark CE Interrusi 1987 Morphine-6-glucuronide, a potent mu agonist Life Sci 41 2845 2849 2826951 1:CAS:528: DyaL1cXhs1arsQ%3D%3D 10.1016/0024-3205(87)90431-0 (Pubitemid 17165867)
98. RT Penson SP Joel K Bakhshi SJ Clark RM Langford ML Slevin 2000 Randomized placebo-controlled trial of activity of the morphine glucuronides Clin Pharmacol Ther 68 667 676 11180027 1:CAS:528:DC%2BD3MXht1Sjsbo%3D 10.1067/mcp.2000.111934 (Pubitemid 32059993)
99. RT Penson SP Joel A Gloyne S Clark ML Slevin 2005 Morphine analgesia in cancer pain: role of the glucuronides J Opioid Manag 1 83 90 17319252
100. O Dale J Thoner T Nilsen T Tveita PC Borchgrevink P Klepstad 2007 Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery Eur J Clin Pharmacol 63 837 842 17619868 1:CAS:528:DC%2BD2sXoslGns70%3D 10.1007/s00228-007-0329-x (Pubitemid 47237900)
101. G D'Honneur A Gilton P Sandouk JM Scherrmann P Duvaldestin 1994 Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morhine Anesthesiology 81 87 93 8042814 10.1097/00000542-199409001- 00086
102. J Lötsch R Schmidt G Vetter H Schmidt E Niederberger G Geisslinger I Tegeder 2002 Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein J Neurochem 83 241 248 12423235 10.1046/j.1471-4159.2002.01177.x (Pubitemid 35191390)
103. F Bourasset S Cisternino J Temsamani JM Scherrmann 2003 Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein- mediated at the blood-brain-barrier J Neurochem 86 1564 1567 12950465 1:CAS:528:DC%2BD3sXnsV2iurY%3D 10.1046/j.1471-4159.2003.01990.x (Pubitemid 37174273)
104. J Lötsch M Zimmermann J Darimont C Marx R Dudziak C Skarke G Geisslinger 2002 Does the A118G polymorphism at the μ-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology 97 814 819 12357145 10.1097/00000542-200210000-00011
105. C Woffindin NA Hoenich 1995 Hemodialyzer performance: a review of the trends over the past two decades Artif Organs 19 1113 1119 8579523 1:STN:280:DyaK287ks1yltA%3D%3D 10.1111/j.1525-1594.1995.tb02272.x
106. J Gjessing 2008 Studies on peritoneal dialysis Kidney Int Suppl 108 S18 S25 18379543 10.1038/sj.ki.5002634
107. T Fujimura Y Uchi M Fukuda M Miyazaki S Uezumi T Hiyoshi 2004 Development of a dialyzer with enhanced internal filtration to increase the clearance of low molecular weight proteins J Artif Organs 7 149 153 15558337 1:CAS:528:DC%2BD2cXhtVSitLjK 10.1007/s10047-004-0257-9 (Pubitemid 40064341)
108. L Lucchi GB Fiore G Guadagni S Perrone V Malaguti F Caruso R Fumero A Albertazzi 2004 Clinical evaluation of internal hemodiafiltration (iHDF): a diffusive-convective technique performed with internal filtration enhanced high-fluc dialyzers Int J Artif Organs 27 414 419 15202820 1:STN:280: DC%2BD2czgtFKisw%3D%3D
109. FDA Guidance for Industry (1998) Pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labelling. Available at: http://www.fda.gov/cder/guidance/1449fnl.pdf
110. EMEA (2004) Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function. Available at: http://www.emea.europa.eu/pdfs/human/ewp/022502en.pdf
111. Golper TA, Marx MA, Shuler C et al (1996) Drug dosage in dialysis patients. In: Jacobs C, Kjellstrand CM, Koch KM (eds) Replacement of Renal Function by Dialysis. Kluwer, Boston, pp 750-614
112. Aronoff GR, Bennett WM, Berns JS et al (2007) DrugpPrescribing in renal failure: dosing guidelines for adults and children, 5th edn. American College of Physicians, Philadelphia
113. A Asari H Iles-Smith Y-C Chen O Naderer MA Johnson GJ Yuen V Otto JA Dunn R Gokal 2007 Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure Br J Clin Pharmacol 64 738 744 17662093 1:CAS:528:DC%2BD1cXhtVKrtrs%3D
114. BS Decker BA Mueller KM Sowinski 2007 Drug dosing considerations in alternative hemodialysis Adv Chronic Kidney Dis 14 17 26 10.1053/j.ackd.2007.03. 004 (Pubitemid 46977285)
115. KM Sowinski SJ Magner A Lucksiri MK Scott MJ Hamburger BA Mueller 2008 Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing Clin J Am Soc Nephrol 3 355 361 18235142 1:CAS:528:DC%2BD1cXhtVWlt7zE 10.2215/CJN.02920707
116. LL Ponto RD Schoenwald 1990 Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review (part I) Clin Pharmacokinet 18 381 408 2185908 1:CAS:528:DyaK3cXkslSnur0%3D 10.2165/00003088-199018050-00004
117. DC Brater SA Anderson D Brown-Cartwright 1986 Response to furosemide in chronic renal insufficiency: rationale for limited doses Clin Pharmacol Ther 40 134 139 3731676 1:STN:280:DyaL283ntlSjtQ%3D%3D
118. GJ Sanderink CG Guimart ML Ozoux NU Jariwala UA Shukla BX Boutouyrie 2002 Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment Thromb Res 105 225 231 11927128 1:CAS:528:DC%2BD38Xitlaltb8%3D 10.1016/S0049-3848(02)00031-2 (Pubitemid 34260945)
119. JS Hulot C Vantelon S Urien A Bouzamondo I Mahé A Ankri G Montalescot P Lechat 2004 Effect of renal failure on the pharmacokinetics of enoxaparin and consequences on dose adjustment Ther Drug Monit 26 305 310 15167633 1:CAS:528:DC%2BD2cXksVKgtrs%3D 10.1097/00007691-200406000-00015 (Pubitemid 38703019)
120. M Noris G Remuzzi 1999 Uremic bleeding: closing the circle after 30 years of controversies? Blood 94 2569 2574 10515859 1:CAS:528:DyaK1MXmslagtbs%3D
121. KG Fischer 2007 Essentials of anticoagulation in hemodialysis Hemodial Int 11 178 189 17403168 10.1111/j.1542-4758.2007.00166.x (Pubitemid 46534550)
122. DF Brophy DA Sica 2007 Use of enoxaparin in patients with chronic kidney disease: safety considerations Drug Saf 30 991 994 17973538 1:CAS:528: DC%2BD2sXhsVGqurjI 10.2165/00002018-200730110-00001
123. J Fareed D Hoppensteadt J Walnga O Iqbal Q Ma W Jeske T Sheikh 2003 Pharmacodynamic and harmacokinetic properties of enoxaparin: implications for clinical practice Clin Pharmacokinet 42 1043 1057 12959635 1:CAS:528: DC%2BD3sXosFCntb4%3D 10.2165/00003088-200342120-00003 (Pubitemid 37186676)
124. M Edholm EG Berglund T Salmonson 2008 Regulatory aspects of pharmacokinetic profiling in special populations Clin Pharmacokinet 48 693 701 10.2165/00003088-200847110-00001
125. Y Zhang L Zhang S Abraham S Apparaju T-C Wu JM Strong S Xiao AJ Atkinson Jr KE Thummel JS Leeder C Lee GJ Burckart LJ Lesko S-M Huang 2009 Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications Clin Pharmacol Ther 85 305 311 19020495 1:CAS:528:DC%2BD1MXit1Ogurg%3D 10.1038/clpt.2008.208
126. C Peck W Barr L Benet, et al. 1992 Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development Clin Pharmacol Ther 51 465 473 1563216 1:STN:280: DyaK383isVGlsw%3D%3D
127. L Aarons LP Balant F Mentré, et al. 1994 Population approaches in drug development: report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software Eur J Clin Pharmacol 46 389 391 7957530 1:STN:280:DyaK2M%2FksFykug%3D%3D 10.1007/BF00191898
128. FDA Guidance for Industry (1999) Population pharmacokinetics. Available at: http://www.fda.gov/cder/guidance/1852fnl.pdf
129. N Toublanc ML Sargentini-Maier B Lacroix P Jacqmin A Stockis 2008 Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations Clin Pharmacokinet 47 333 341 18399714 1:CAS:528:DC%2BD1cXntVWgsbY%3D 10.2165/00003088-200847050-00004
130. AS Zandvliet JHM Schellens JH Beijnen ADR Huitema 2008 Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology Clin Pharmacokinet 47 487 513 18611060 1:CAS:528:DC%2BD1cXhtVOgu7fJ 10.2165/00003088-200847080-00001 (Pubitemid 351969825)
131. TB Tzeng DW Schneck BK Birmingham PD Mitchell H Zhang PD Martin LP Kung 2008 Population pharmacokinetics of rosuvastatin: implications of renal impairment, race and dyslipidaemias Curr Med Res Opin 24 2575 2585 18674408 1:CAS:528:DC%2BD1cXhtlKit7rK 10.1185/03007990802312807
132. Food and Drug Administration (2004) Enoxaparin injection drug approval. Available at: www.fda.gov/medwatch/SAFETY/2004/lovenox-PI.pdf
133. J-S Hulot G Montalescot P Lechat J-P Collet A Ankri S Urien 2005 Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome Clin Pharmacol Ther 77 542 552 15961985 1:CAS:528:DC%2BD2MXlt1Gqt7g%3D 10.1016/j.clpt.2005.02.012 (Pubitemid 40824967)
134. L Vidal M Shavit A Fraser M Paul L Leibovici 2005 Systematic comparison of four sources of drug information regarding adjustment of dose for renal function Br Med J 331 263 266 10.1136/bmj.38476.471088.3A (Pubitemid 41097909)
135. Committee JF (2004) British national formulary, 48th edn. London, British Medical Association and Royal Pharmaceutical Society of Great Britain, London
136. Sweetman SC (ed) (2004) Martindale; the complete drug reference. Pharmaceutical Press, London
137. McEvoy GK, Miller J, Snow EK, Welsh OH, Litvak K (eds) (2004) American hospital (AHFS) drug information. American Society of Health-System Pharmacists, Bethesda
138. Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I et al (eds) (1999) Drug prescribing in renal failure: dosing guidelines for adults (1999) American College of Physicians, Philadelphia
139. Letters to the Editor 2005 Dose adjustment in renal impairment Br Med J 331 292 294